Porphyria; thromboembolic events. Evaluate patients for hypothyroidism, adrenocortical deficiency, hyperprolactinemia & pituitary or hypothalamic tumours prior to therapy. Monitor therapy carefully to minimize incidence of ovarian enlargement or ovarian hyperstimulation syndrome (OHSS), multiple & ectopic pregnancy, pregnancy loss, reproductive system neoplasms, congenital malformation.